Subject to appropriation, the Department shall provide grants totaling $3 million dollars for research on the use and efficacy of psilocybin for the treatment of conditions listed in the act, with such appropriation being made from the Opioid Addiction Treatment and Recovery Fund.

The Department shall prepare annual reports for the Governor, Lieutenant Governor, and the General Assembly on the implementation and outcomes of psilocybin use under this act.

No state agency shall disclose to the federal government or any unauthorized third party the statewide list or any individual information of persons who meet the requirements of this act.

Additionally, this act modifies current law on the use of investigational drugs and devices for individuals with terminal illnesses to include individuals with life-threatening or severely debilitating conditions or illnesses. Currently, investigational drugs shall not include Schedule I controlled substances. This act repeals that prohibition.

Finally, this act requires the Department, in collaboration with a Missouri university hospital or contract research organizations conducting FDA-approved trials, to conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of psilocybin, for the treatment of patients suffering post-traumatic stress disorder, major depressive disorder, substance use disorders, or who require end-of-life care, as described in the act. Such study shall include a study of the use of psilocybin to treat such conditions, as well as a literature review and the submission of various reports. No person participating in the study shall be subject to criminal or civil liability or sanction for participating, except in cases of gross negligence or willful misconduct.

This act is similar to HCS/HB 1830 (2024), HB 1154 (2023), and SB 614 (2023).

SARAH HASKINS